Bristol-Myers Squibb Co. (BMY)

From the record

Bristol-Myers Squibb Co.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Bristol-Myers Squibb Co.'s 10 filed years say what it did: revenue went from $19 billion in fiscal 2016 to $48 billion in fiscal 2025, up 10.6% a year; it rose in 6 of 9 years; the deepest fall was 3% from fiscal 2021 to fiscal 2023; net income was positive in 8 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Bristol-Myers Squibb Co.'s diluted share count shrank about 1.7% a year, and dividends and buybacks returned about 46% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 5 sales and 0 purchases of their own stock on the open market in the year to 2026-11-06 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Bristol-Myers Squibb Co. earned about 38 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 38 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 79 cents per dollar of assets, and net share issuance: its share count grew 0.6% over the year (the filed statements).

From the record

Bristol-Myers Squibb Co.'s standing among 315 graded names in its industry family: revenue of $48 billion in fiscal 2025 ranks in the top 2% by size; a net margin of 14.6% ranks in the top 14%; revenue growth of 1.4% a year over the last 3 filed years ranks in the bottom 40% (its annual reports).

From the record

Bristol-Myers Squibb Co.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Boerner, Christopher S. (Chief Executive Officer, as filed), filing under that title since 2023-11-03, 3 years (bottom 32% of its family); the 24 officers and directors filing in the last fifteen months have been on the record a median of 4.5 years (bottom 29%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 24 people in charge now (top 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Bristol-Myers Squibb Co.'s room to grow, from the newest filed statements (fiscal 2025): cash of $10 billion against debt of $45 billion leaves -38.4% of its assets as net cash, bottom 3% of its family; cash from operations less capital spending is 26.7% of revenue (top 8%); a gross margin of 71.1% (top 50%); research spending of 20.6% of revenue (bottom 26%) (its annual report).

From the record

Bristol-Myers Squibb Co.'s growth drivers, from the filed years to fiscal 2025: revenue grew 1.4% a year over the last three filed years against 10.6% over all 10, slowing (bottom 36% of its family); the newest year grew -0.2% (bottom 37%); research spending grew 1.5% a year (top 50%); capital spending grew 5.5% a year (top 33%) (its annual reports). Bristol-Myers Squibb Co. reported 14 product lines in fiscal 2025: Eliquis at $14 billion (30%), Opdivo at $10 billion (21%), Orencia at $3.7 billion (8%), and 11 more; 9 of 14 grew against the year before (its annual report).

From the record

Bristol-Myers Squibb Co.'s newest year against its own record: revenue of $48 billion in fiscal 2025 came in 2.5% below the $49 billion its prior three years' pace pointed to (bottom 48% of its family); net income of $7.1 billion against a prior three-year average of $1.8 billion (top 4%); a net margin of 14.6% against 4.3% before (bottom 49%) (its annual reports).